Register Now |
Reserve Housing |
Late-Breaking Abstract Submission Period Now Open
With the late-breaking abstract submission period open for a limited time, SITC invites members and nonmembers alike to showcase timely findings, ground-breaking data as well as high impact results by submitting late-breaking, original research today through August 25, 2014. All submitted abstracts will be considered for oral presentations, unless otherwise noted by the submitting author.
New Category for Late-Breaking Submission
An “Other” category has been added during the late-breaking submission period to accommodate abstracts that do not fit under specific submission categories.
Late-Breaking Abstract Submission Details
- Submission Period: August 11, 2014 - August 25, 2014
- Free submission for SITC members and nonmembers alike
- Criteria - More details can be found on the submission site here.
Benefits of Acceptance
- Accepted abstracts will be available to all Annual Meeting attendees in printed program materials and published in the Journal for ImmunoTherapy of Cancer (JITC)
- Several slots have been reserved for oral presentations of abstracts that
- are scientifically important and exciting to the anticipated audience
- include significant advances to existing science
- are high-novelty and provide teaching moments
- are scientifically important and exciting to the anticipated audience
- All accepted abstracts not selected for oral presentation will be included as poster presentations
- Chance to showcase your science to more than 1,100 anticipated meeting attendees
Late-Breaking Submission Categories
- Adoptive Immunotherapy
- Barriers to Successful Vaccines
- Clinical Trials in Progress
- Coinhibition and Costimulation: Targets and Strategies
- High Throughput Technologies: Determinants of the Immune Response to Cancer
- Immune Monitoring
- Immunopotentiation by Radiotherapy: Mechanisms and Opportunities
- Inflammation, Innate Immunity and Microbiome
- Lung Cancer: Immunology and Immunotherapy
- Metabolism and Molecular Targeted Therapies
- Tumor Microenvironment and Immunosuppression
- Other
